Predictors And Management Of Inadequate Response To JAK Inhibitors In Alopecia Areata

The document reviews the predictors and management strategies for patients with alopecia areata who show inadequate response to JAK inhibitors. It examines studies on the efficacy and safety of JAK inhibitors like baricitinib, ritlecitinib, and tofacitinib, often used with corticosteroids and minoxidil. While some patients benefit from these treatments, others do not, and switching between JAK inhibitors can sometimes improve outcomes. Additionally, dupilumab may be effective, especially for patients with both alopecia areata and atopic dermatitis. The research highlights the complexity of treating alopecia areata and emphasizes the need for personalized treatment approaches.